Workshop
„Tumor immunology“ of the DGfi
21st of May 2015
Location: Lecture Hall 4 at the University Hospital Kroellwitz, Halle

Chair: Marc Schmitz, Selvan Senthamil

12.45 – 13.00 Barbara Seliger: Introduction

13.00 – 13.15 Zhao Fang (Essen, D)
Genetic heterogeneity of intra-patient metastases restricts T-cell recognition of malignant melanoma

13.15 – 13.30 Simon Jasinski-Bergner (Halle, D)
HLA-E expression in renal cell carcinoma and its association with immune cell infiltration

13.30 – 13.45 Elisabeth Geyer (Dresden, D)
Phenotype of infiltrating human 6-sulfo LacNAc dendritic cells in renal and colon cancer

13.45 – 14.00 Dagmar Quandt (Halle, D)
Chemotherapy induced modulation of immune recognition in murine and human tumors

14.00 – 14.15 Kathrin Renner (Regensburg, D)
Glycolytic or mitochondrial restriction preserves human CD4 and CD8 T cell effector function

14.15 – 14.30 Frank Momburg (Heidelberg, D)
Altered T and NK cell activation in an simulated tumor microenvironment

14.30 – 14.45 Elisa Cappuzzello (Padova, I)
Combined therapy of CIK cells and monoclonal antibodies for ovarian cancer: a preclinical study

14.45 – 15.00 Stefanie Koristka (Dresden, D)
Flexible antigen-specific redirection of human regulatory T cells via a novel universal chimeric antigen receptor system

15.00 - 15.15 Elena Faitschuk (Cologne, D)
A novel CAR in a physiologic antibody format to redirect modified T cells

Coffe Break

...
Chair: Dagmar Riemann, Michael Bachmann

15.45 –16.15 Samir Khleif (Augusta, USA)
Strategies and design for combination immunotherapie

16.15 –16.30 Marc Cartellieri (Dresden, D)
Switching T cells on and off: A novel modular retargeting platform technology for precise control of CAR T cell reactivity

16.30 – 16.45 Lucia Poncette (Berlin, D)
Human HLA-DR4-restricted T cell receptors against NY-ESO-1 from a non-tolerant host

16.45 –17.00 Eva Amann (Mainz, D)
HLA-A2-restricted MDM2 (81-88) epitope as a new target antigen for TCR therapy

17.00 – 17.15 Sara Valpione (Padova, I)
Personalized medicine: development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab

17.15 – 17.30 Ann-Charlott Schneider (Cologne, D)
NK-cell based immunoligands as novel treatment option against haematological tumors

17.30 – 17.45 Alexandra Martyniszyn (Cologne, D)
Dual targeting by a bispecific Chimeric Antigen Receptor (CAR) for the recognition of antigen-loss subset of leukemic cells

17.45 – 18.00 Claudia Arndt (Dresden, D)
Improved killing of AML blasts by dual-targeting of CD123 and CD33 via a Ab-based modular T cell retargeting system

18.00 – 18.20 Thomas-Oliver Kleen (Berlin, D)
Next generation immune monitoring using epigenetic markers

Summary Hinrich Abken

We thank our sponsors: Beckman Coulter GmbH, Becton Dickinson GmbH, Biodesix, Bristol-Myers Squibb (3.000 €), City of Halle, DFG, DGfI, Epiontis GmbH, iba Solutions for Life Sciences, JPT Peptide Technologies GmbH, Lipocalyx GmbH, Miltenyi Biotec GmbH, Ministerium für Wissenschaft und Wirtschaft Sachsen-Anhalt, NHDyeAGNOSTICS, Pfizer Pharma GmbH (1.000 €), Saalesparkasse Halle, Sarstedt, SERVA GmbH, SITC